Skip to main content
HIF2A Germline-Mutation-Induced Polycythemia in a Patient with VHL-Associated Renal-Cell Carcinoma
Cancer Biology & Therapy
  • Qiuli Liu
  • Dali Tong
  • Gaolei Liu
  • Yuting Yi
  • Dianzheng Zhang, Philadelphia College of Osteopathic Medicine
  • Jun Zhang
  • Yao Zhang
  • Zaoming Huang
  • Yaoming Li
  • Rongrong Chen
  • Yanfang Guan
  • Xin Yi
  • Jun Jiang
Document Type
Publication Date
In this study, we report here a rare case of polycythemia and cRCC in the same patient, which may be helpful in understanding clinical features and molecular mechanisms underlying VHL-mutation-associated cRCC and polycythemia induced by germline mutation of HIF2A. Firstly, we identified a rare but well studied germline mutation resulting in polycythemia in HIF2A (c.1609G>A, p.Gly537Trp) in the blood of the patient and his daughter. Meanwhile, we identified an inactivating VHL mutation (c.391A>T, p.N131Y), as well as TP53 mutation(c.977A>T, p.E326V) and mTOR mutation(c.7498A>T, p.I2500F) in renal cancer tissue. Moreover, protein levels of VHL, HIF1A, HIF2A, EPO, and VEGF estimated by immunohistochemical staining substantiated hyperactivation of the oxygen-sensing pathway. In addition, we identified 158 somatic SNP/indel mutations, including 90 missense/nonsense/splice/stop-loss mutations by whole-exome sequencing (WES) of the tumor specimen and matched normal DNA.
PubMed ID

This article was published in Cancer Biology & Therapy, Volume 18, Issue 12, Pages 944-947.

The published version is available at

Copyright © 2017.

Citation Information
Qiuli Liu, Dali Tong, Gaolei Liu, Yuting Yi, et al.. "HIF2A Germline-Mutation-Induced Polycythemia in a Patient with VHL-Associated Renal-Cell Carcinoma" Cancer Biology & Therapy Vol. 18 Iss. 12 (2017) p. 944 - 947
Available at: